Combination therapy with lipid prodrug liposomes reshapes disease-associated neutrophils to promote the cancer-immunity cycle

Table 1 Artificial intelligence–assisted design of PEG-modified MLP liposomes incorporating different phospholipid types

Phospholipid	Particle size (nm)	PDI	Zeta potential (mV)	Encapsulation efficiency (%)
HSPC	240.54	0.14	− 7.78	73.35
DSPC	223.87	0.16	− 10.75	75.58
DPPC	221.30	0.16	− 11.01	76.41
DMPC	217.47	0.16	− 12.25	76.54
DLPC	217.32	0.16	− 11.60	76.40
POPC	222.01	0.16	− 10.46	76.29
DOPC	223.92	0.16	− 10.75	75.58
DSPG	230.77	0.16	− 14.26	71.11
DPPG	230.53	0.16	− 15.55	74.63
DMPG	227.22	0.16	− 15.75	74.65
POPG	250.02	0.14	− 11.68	68.07
DOPG	230.51	0.16	− 14.09	71.25
POPE	228.11	0.16	− 15.34	74.46
DOPE	227.11	0.16	− 14.33	71.34
DOTAP	222.41	0.16	7.4	76.85
DPPS	230.49	0.16	− 14.53	71.52

The characteristics include particle size, PDI, zeta potential, and encapsulation efficiency
HSPC, Hydrogenated Soy Phosphatidylcholine; DSPC, Distearoylphosphatidylcholine; DPPC, Dipalmitoylphosphatidylcholine; DMPC, Dimyristoylphosphatidylcholine; DLPC, Dilauroylphosphatidylcholine; POPC, 1-Palmitoyl-2-oleoylphosphatidylcholine; DOPC, Dioleoylphosphatidylcholine; DSPG, Distearoylphosphatidylglycerol; DPPG, Dipalmitoylphosphatidylglycerol; DMPG, Dimyristoylphosphatidylglycerol; POPG, 1-Palmitoyl-2-oleoylphosphatidylglycerol; DOPG, Dioleoylphosphatidylglycerol; POPE, 1-Palmitoyl-2-oleoylphosphatidylethanolamine; DOPE, Dioleoylphosphatidylethanolamine; DPPS, (2,3-Dioleoylpropyl)-trimethylammonium chloride; Dipalmitoylphosphatidylserine

ISSN: 1477-3155